Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma

SK Barta, J Zain, AW MacFarlane IV, SM Smith… - … Myeloma and Leukemia, 2019 - Elsevier
Background Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) are
frequently expressed in T-cell lymphomas. This provides a rationale for exploration of …
被引用次数：106 相关文章

Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma

SK Barta, J Zain, AW MacFarlane… - Clinical …, 2019 - mdanderson.elsevierpure.com
Background: Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) are
frequently expressed in T-cell lymphomas. This provides a rationale for exploration of …

Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma

SK Barta, J Zain… - Clinical …, 2019 - clinical-lymphoma-myeloma …
Background Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) are
frequently expressed in T-cell lymphomas. This provides a rationale for exploration of …

Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma

SK Barta, J Zain, AW MacFarlane 4th… - Clinical lymphoma …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) are
frequently expressed in T-cell lymphomas. This provides a rationale for exploration of …

Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.

SK Barta, J Zain, AW MacFarlane, SM Smith… - … Myeloma & Leukemia, 2019 - europepmc.org
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory
Mature T-cell Lymphoma. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …

[引用][C] Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma

SK Barta, J Zain, AW MacFarlane, SM Smith… - Clinical Lymphoma …, 2019 - cir.nii.ac.jp
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory
Mature T-cell Lymphoma | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …
[HTML] nih.gov

[HTML][HTML] Phase II Study of the PD1-inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma

SK Barta, J Zain, AW MacFarlane IV… - … , myeloma & leukemia, 2019 - ncbi.nlm.nih.gov
Phase II Study of the PD1-inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory
Mature T-cell Lymphoma - PMC Back to Top Skip to main content NIH NLM Logo Access keys …

Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.

SK Barta, J Zain, AW MacFarlane, SM Smith… - … Myeloma & Leukemia, 2019 - europepmc.org
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory
Mature T-cell Lymphoma. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …